Holen Sie sich die Stockscreener-App
6.27
5.56%
0.33
Handel nachbörslich:
6.35
0.08
+1.28%
Edesa Biotech Inc Aktie (EDSA) Neueste Nachrichten
Edesa Biotech Inc. Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Commercial R&D Costs PersistMargin Compression Risk - newsline.com
EDSA Q1 2026 Earnings: Misses EPS Estimates Amid Pre-Revenue Stage, Stock Rises 2.65%Mid-Term Outlook - newsline.com
Why Did EDSA Stock Rally More Than 70% Today? - Stocktwits
Edesa Biotech announces $3.5M PIPE financing - MSN
Edesa Biotech announces $3.5M private placement - TipRanks
Edesa Biotech Announces Insider-Led PIPE Financing Agreement - TipRanks
Edesa Biotech secures $3.5 million private placement financing - Investing.com
Edesa Biotech Raises $3.5 Million in Private Placement, Issues 729,241 Shares - TradingView
Edesa Biotech (Nasdaq: EDSA) sets $3.5M PIPE led by CEO - Stock Titan
CEO backs $3.5M raise to advance Edesa vitiligo work - Stock Titan
Edesa Biotech, Inc. announced that it expects to receive $3.42014 million in funding - marketscreener.com
Edesa Biotech Company Profile & Introduction - Moomoo
EDSA Stock Rallied Over 50% Today: What’s Ahead For The Small-Cap Biotech? - Stocktwits
Edesa reports exploratory data on AKI treatment candidate - Investing.com UK
Edesa reports exploratory data on AKI treatment candidate By Investing.com - Investing.com South Africa
Edesa Biotech Says Paridiprubart Linked to Lower Risk of Death in Acute Kidney Injury Patients - marketscreener.com
Exploratory AKI data show lower mortality with paridiprubart at Edesa (NASDAQ: EDSA) - Stock Titan
Edesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney Injury - GlobeNewswire
Acute Respiratory Distress Syndrome Market to Grow Steadily at a 3.8% CAGR Through 2036, Supported by Emerging ARDS Therapies | DelveInsight - GlobeNewswire Inc.
Edesa Biotech (NASDAQ: EDSA) CEO receives 1,671 restricted share units - Stock Titan
Edesa Biotech Shareholders Approve Directors and Compensation Plans - The Globe and Mail
Edesa Biotech (EDSA) director receives 19,000 restricted share units - Stock Titan
Edesa Biotech (EDSA) director granted 19,000 restricted share units - Stock Titan
Edesa Biotech (EDSA) director receives 19,000-share RSU award vesting over 12 months - Stock Titan
Edesa Biotech (EDSA) CFO receives 64,609 restricted share units under 2019 plan - Stock Titan
Edesa Biotech (EDSA) president awarded 64,609 restricted share units - Stock Titan
Edesa Biotech (EDSA) director receives 19,000-share equity grant, holds 30,000 - Stock Titan
[Form 4] Edesa Biotech, Inc. Insider Trading Activity - Stock Titan
Edesa Biotech (EDSA) director Da David Liu receives 19,000-share equity grant - Stock Titan
Edesa Biotech (NASDAQ: EDSA) boosts equity plan and reelects full board - Stock Titan
EDSA - Finviz
Edesa Biotech, Inc. (EDSA) Presents at Dermatology Drug Development Summit 2026Slideshow - Seeking Alpha
Edesa Biotech, Inc.Common Shares (NQ: EDSA - FinancialContent
EDSA: Preparing for Mid-2026 Start to Phase 2 Vitiligo Trial - Zacks Small Cap Research
Edesa Biotech Inc. (EDSA) Q1 2026 Earnings: Wider Than Expected Loss as Clinical Pipeline ProgressesTangible Book Value - Newser
EDSA Stock Price, Quote & Chart | EDESA BIOTECH INC (NASDAQ:EDSA) - ChartMill
Key facts: Edesa Biotech Q2 Loss $4.2M; to Present AKI Data - TradingView
Edesa Biotech, Inc. (EDSA) Presents at Respiratory Innovation Summit 2026Slideshow (NASDAQ:EDSA) 2026-05-19 - Seeking Alpha
EDSA stock soars more than 700% so far this year: Wall Street eyes further upside in run up to acute kidney injury data reveal - MSN
What's going on in today's session - ChartMill
Edesa Biotech to Present New Data on Paridiprubart in Acute Kidney Injury at European Nephrology Conference - marketscreener.com
EDSA Should I Buy - Intellectia AI
Stonepine entities report 30,000-share stake in Edesa Biotech (EDSA) - Stock Titan
EDESA (EDSA) Schedule 13G/A amendment: Nantahala and principals report 0 shares - Stock Titan
Point72, Steven Cohen report 2 Edesa Biotech shares (NASDAQ: EDSA) - Stock Titan
Rubric Capital and Rosen Hold 7.74% of EDSA (NASDAQ: EDSA) - Stock Titan
Edesa Biotech to issue 90% of CEO’s salary as restricted share units - Investing.com UK
Edesa Biotech Boosts CEO Equity-Based Compensation Structure - TipRanks
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):